PMA device
Amplatzer Septal Defect Occluder
Abbott Medical · Occluder, Patent Ductus, Arteriosus (MAE, Class III) · First FDA decision Aug 14, 2015, newest Aug 14, 2015Congenital heart disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
11
Naming "Amplatzer Septal Defect"
MAUDE reports
0
Brand "Amplatzer Septal Defect", since 2015
PubMed studies
0
Mentioning "Amplatzer Septal Defect"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Amplatzer Septal Defect Occluder
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- AMPLATZER SEPTAL DEFECT OCCLUDERPMA supplement
P000039-S050 · Decided Aug 14, 2015 · 154 days after receipt · Normal 180 Day Track No User Fee
Device type: OCCLUDER, PATENT DUCTUS, ARTERIOSUS (MAE) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Amplatzer Septal Defect", any status and sponsor, newest update first.
Assiut UniversityAcademic, hospital or other
NCT07715032 · 85 participants (planned) · Start Aug 1, 2026 · Primary completion Oct 1, 2027
Device: • Amplatzer™ Ductal Occluder (ADO) • Amplatzer™ Muscular VSD Occluder • Amplatzer™ Membranous VSD Occluder · For: VSD; Pediatric Cardiology
10 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Amplatzer Septal Defect", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAE
989 reports: 371 malfunction, 557 injury, 61 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2192-2008 · Started Apr 25, 2008 · Posted by FDA Sep 3, 2008
Reason given: AGA Medical Corporation has identified an issue with outer pouch seal integrity within one production lot of 10 French 45/80 delivery systems and one lot of 24 mm Sizing Balloon. We have not observed incomplete seals with the inner pouch. An intact inner pouch seal will maintain device sterility. AGA is asking that...
Cause as FDA categorized it: Packaging process control
1 more recall records with a free account
Published research
The most relevant PubMed records for "Amplatzer Septal Defect"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MAE.
- Amplatzer Duct Occluder, Amplatzer Duct Occluder II, Amplatzer Piccolo OccluderAbbott Medical · PMA 2024
- Amplatzer Septal Occluder,cribriform Ocluder,and Delivery and Exchange SystemsAbbott Medical · PMA 2016
- Nit-Occlud PdaPfm Medical, Inc. · PMA 2024
- Amplatzer Piccolo OccluderAbbott Medical · PMA 2023
- Pma Nit-Occlud PdaPfm Medical, Inc. · PMA 2016
- Amplatzer Multi-Fenestrated Septal Occluder ? ?cribriform? OccluderAbbott Medical · PMA 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.